Sartorius
Trending Articles
Related Content
Pharmaceutical
Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024
Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Regulatory
Polyplus expands GMP offer with protein production and adds GMP capacity in Belgium
Polyplus (part of Satorius) company, Xpress Biologics, has received a good manufacturing practice (GMP) certification for recombinant protein production and renewed the January 2023 GMP certification for DNA production at the facility located in Belgium
Finance
MarkHerz and Polyplus collaborate to advance CGT process standards and lower costs
Polyplus (part of Sartorius) has inked a collaboration with pioneering Korean cell and gene therapy (CGT) CDMO, MarkHerz, to set new CGT efficiency standards focused on decreasing cost and increasing quality per dose of a therapeutic product